A symptom endpoint from MARIPOSA: 43.6 months against 29.3 before things get worse

Design

secondary and exploratory endpoint analysis of a phase 3 randomised trial

Population

previously untreated EGFR-mutant advanced non-small-cell lung cancer; median follow-up 37.8 months

Primary outcome

time to symptomatic progression (symptom worsening requiring intervention or treatment change, or death)

Effect

median 43.6 vs 29.3 months, hazard ratio 0.69 (95% CI 0.57-0.83), p<0.0001

Radiographic progression-free survival tells a patient when a scan changed, which is not the question they asked. In the phase 3 MARIPOSA trial of amivantamab plus lazertinib against osimertinib in previously untreated EGFR-mutant advanced non-small-cell lung cancer, a secondary endpoint was defined as time to symptomatic progression: the time from randomisation until disease-specific symptom worsening that required clinical intervention or a treatment change, or death.

At the final overall survival analysis, with median follow-up of 37.8 months, median time to symptomatic progression was 43.6 months with the combination against 29.3 months with osimertinib, a hazard ratio of 0.69 (95% CI 0.57 to 0.83, p < 0.0001). The endpoint correlated strongly with both progression-free and overall survival, and the combination reduced deaths following a symptomatic progression event.

The endpoint is the point. Fourteen extra months before symptoms force a change in treatment is a statement a patient can weigh, and it sits in the same conversation as the toxicity of the combination - amivantamab's infusion reactions and skin effects are not trivial, and the trade is between tolerating those now and delaying symptomatic deterioration later. That correlation with the established endpoints also means it is not independent evidence of benefit: it is a more interpretable expression of a benefit already demonstrated.

• Use time to symptomatic progression, not radiographic progression-free survival, when explaining what a regimen buys.
• Frame the choice as tolerating combination toxicity now against delaying symptomatic decline later.
• Note the endpoint correlates strongly with progression-free and overall survival - it is not additional evidence of benefit.
• The definition includes death, so read the censored exploratory analysis before quoting it as a pure symptom measure.
• Availability and cost of amivantamab will decide this in most Indian centres, and neither is addressed here.

Why it matters

It gives a first-line lung cancer conversation an endpoint a patient can actually use, instead of a scan interval.

Don't overread it

This is a secondary endpoint, highly correlated with the primary and survival endpoints, so it does not add independent evidence of benefit.

The statistics, in plain English

A hazard ratio of 0.69 with an interval of 0.57 to 0.83 means the rate of symptomatic worsening was about 30% lower, and the whole interval sits below 1.0. But this was a secondary endpoint in a trial powered for progression-free survival, and it correlates strongly with the primary and survival endpoints - so it should be read as a clearer description of an established benefit, not as a separate one. The exploratory analysis censoring deaths matters, because a composite including death is not purely a symptom measure.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.